LBA1 Ceralasertib (C) + durvalumab (D) in patients (pts) with locally advanced (LA) or metastatic (m) NSCLC who progressed on or after anti-PD-(L)1 and platinum-based chemotherapy (CT): Results from LATIFY

4.5 (0.4-31.9) 3.8 (0-31.7)3.0 (0.3-27.6)CI, confidence interval; HR, hazard ratio; mo, months.Conclusions: C+D did not demonstrate a statistically significant improvement in OS vs docetaxel.C+D had manageable toxicity and AEs were consistent with the known safety profiles of each agent.

Authors

Institutions

Publication Details

Journal
ESMO Open
Published
2026-03-17
DOI
https://doi.org/10.1016/j.esmoop.2026.106957
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

LBA1 Ceralasertib (C) + durvalumab (D) in patients (pts) with locally advanced (LA) or metastatic (m) NSCLC who progressed on or after anti-PD-(L)1 and platinum-based chemotherapy (CT): Results from LATIFY

Marie Florescu, P.M. Forde, Katerina Politi, Elvire Pons-Tostivint et al.
ESMO Open
Lung Cancer Treatments and Mutations
article

LBA1 Ceralasertib (C) + durvalumab (D) in patients (pts) with locally advanced (LA) or metastatic (m) NSCLC who progressed on or after anti-PD-(L)1 and platinum-based chemotherapy (CT): Results from LATIFY

Marie Florescu, P.M. Forde, Katerina Politi, Elvire Pons-Tostivint, L. Bonanno, E. Felip, T. Takahashi, H. Mann, J. Fuentes Pradera, B.C. Cho, J. Wang, A.S. Muntean, B. Besse, Y. Chepka, G. De Castro, J. Rogerio, P. Chen, S.H. Kim, A. Kowalczyk-Tekiela, G. Lo Russo
article en

Abstract

4.5 (0.4-31.9) 3.8 (0-31.7)3.0 (0.3-27.6)CI, confidence interval; HR, hazard ratio; mo, months.Conclusions: C+D did not demonstrate a statistically significant improvement in OS vs docetaxel.C+D had manageable toxicity and AEs were consistent with the known safety profiles of each agent.

ESMO OpenVol. 11
Yonsei University (KR), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Institut Gustave Roussy (FR), Tianjin Medical University Cancer Institute and Hospital (CN), Yale Cancer Center (US), Seoul National University Hospital (KR), Seoul National University Bundang Hospital (KR), Centre Hospitalier Universitaire de Nantes (FR), Shizuoka Cancer Center (JP), Instituto do Câncer do Estado de São Paulo (BR), Institute of Oncology Prof. Dr. Ion Chiricuta (RO), Istituto Oncologico Veneto (IT), AstraZeneca (France) (FR), AstraZeneca (Singapore) (SG), Vall d'Hebron Hospital Universitari (ES), AstraZeneca (Poland) (PL), Centre Hospitalier de l’Université de Montréal (CA), Hospital Universitario de Valme (ES), AstraZeneca (Spain) (ES), AstraZeneca (Canada) (CA), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), Memorial Hospital (US), Sidney Kimmel Comprehensive Cancer Center (US), Vall d'Hebron Institute of Oncology (ES)
Openalex Percentile: Top 19%
Lung Cancer Treatments and Mutations
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.